2008 Article Archive CD from the International Journal of Pharmaceutical Compounding

Sign On

Volume 12, 2008 CD
Six back issues from 2008 on one convenient CD.

Permanent storage and easy retrieval of IJPC articles and formulations.

Print journal articles in color from the PDF file for your marketing needs.
Eliminate long searches through past issues for formulations, compatibility studies, standard operating procedures, marketing ideas, and literature reviews.

Only $95 per CD

This CD contains the following articles listed by volume, issue and page number:


Issues Included
Volume/Issue	Date	Title
Vol. 12 No. 1	January/February 2008	Compounding for Hospice and Cancer Patients
Vol. 12 No. 2	March/April 2008	Compounding Around the World
Vol. 12 No. 3	May/June 2008	Pain Management
Vol. 12 No. 4	July/August 2008	Hormone Replacement Therapy
Vol. 12 No. 5	September/October 2008	Veterinary Compounding
Vol. 12 No. 6	November/December 2008	Arthritis and Immunological Diseases

Volume 12, 2008 CD ARTICLES

Title (Click for Details)	Vol/Issue	Page

Volume 12, 2008 CD ARTICLES
PreScription: Year Number 12…And Still Much Work to Do	Vol. 12 No. 1	4
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration	Vol. 12 No. 1	8
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients	Vol. 12 No. 1	16
Hospice and Compounding Pharmacy: Once Inseperable	Vol. 12 No. 1	28
Disposing of Expired Drugs and Chemicals: New Options for Compounders	Vol. 12 No. 1	38
Websites: Keeping Current in 2008	Vol. 12 No. 1	48
Quality-Control Analytical Methods: Stability Versus Potency Testing: The Madness is in the Method	Vol. 12 No. 1	50
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 5: Verification of Accuracy, Sterility, and Sterilization of Compounded Preparations	Vol. 12 No. 1	54
Calculations: Compounding for Cancer Patients	Vol. 12 No. 1	62
Standard Operating Procedure: Compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996	Vol. 12 No. 1	63
Cyclosporine Topical Gel	Vol. 12 No. 1	64
Diclofenac Sodium 1% Soft-Patch Gel	Vol. 12 No. 1	65
Diclofenac Sodium 1% Soft-Patch Lipophilic Gel	Vol. 12 No. 1	66
Diltiazem 5% in Lipoderm, Veterinary	Vol. 12 No. 1	67
Emetine Hydrochloride 30-mg/mL Injection	Vol. 12 No. 1	68
Flosulide 10-mg/mL Injection	Vol. 12 No. 1	69
Pentoxifylline 20-mg/mL Oral Suspension	Vol. 12 No. 1	70
Piroxicam 1% Soft-Patch Lipophilic Gel	Vol. 12 No. 1	71
Piroxicam 1% Soft-Patch Topical Gel	Vol. 12 No. 1	72
Trimethoprim 10-mg/mL Oral Suspension	Vol. 12 No. 1	73
Specialty Compounding for Improved Patient Care: 2006 National Survey of Compounding Pharmacists	Vol. 12 No. 1	74
Room Temperature Stability of Injectable Succinylcholine Dichloride	Vol. 12 No. 1	83
2007 Reviewers	Vol. 12 No. 1	86
PostScription: Consumer Options for Disposal of Unused Medications	Vol. 12 No. 1	87
PreScription: Compounding Around the World	Vol. 12 No. 2	92
Current Compounding Practices in Europe	Vol. 12 No. 2	94
Compounding Around the World	Vol. 12 No. 2	102
Establishing a Quality-Assurance Program for Hospital Compounding	Vol. 12 No. 2	116
Hormone Therapy: It's Time for a Second Opinion	Vol. 12 No. 2	122
Newsletters: An Essential Marketing Tool	Vol. 12 No. 2	128
Quality-Control Analytical Methods: Minimizing the Probability of Out-of-Specification Preparations: Results that Make You Say…Hmmm!	Vol. 12 No. 2	130
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797>	Vol. 12 No. 2	136
Calculations	Vol. 12 No. 2	145
Acyclovir 5% Topical Ointment	Vol. 12 No. 2	146
Alum 6.5% Topical Cream	Vol. 12 No. 2	147
Aminacrine Hydrochloride 0.1% Cream	Vol. 12 No. 2	148
Butesin Picrate 1% ointment	Vol. 12 No. 2	149
Carbamazepine Topical Preparations	Vol. 12 No. 2	150
Chlorhexidine Gel	Vol. 12 No. 2	151
EDTA 1% Cream	Vol. 12 No. 2	152
Erythromycin 1% and Neomycin Sulfate Ointment	Vol. 12 No. 2	153
Heparin Gel-Cream	Vol. 12 No. 2	154
Hydrogen Peroxide 8% Cream	Vol. 12 No. 2	155
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration	Vol. 12 No. 2	156
Chemical Stability of Tramadol Hydrochloride Injection	Vol. 12 No. 2	161
Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting	Vol. 12 No. 2	163
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration	Vol. 12 No. 2	170
PostScription: Accreditation by the Pharmacy Compounding Accreditation Board: Raising the Bar for Patient Care	Vol. 12 No. 2	174
PreScription: Pain!	Vol. 12 No. 3	180
Topical Treatment of Neuropathic Pain	Vol. 12 No. 3	182
Compounded Local Anesthetics to Minimize Pain from Medical Procedures	Vol. 12 No. 3	192
Dilution and Compounding of Ziconotide for Intrathecal Administration	Vol. 12 No. 3	200
Pharmacy Compounding at the University of Connecticut: Secundum Artem et Scientia	Vol. 12 No. 3	208
Developing and Implementing a Clinical Pharmacy Rotation in a Community Compounding Pharmacy	Vol. 12 No. 3	213
Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards	Vol. 12 No. 3	216
Communication with Pharmacy Technicians: How to Reduce Stress and Improve Pharmacy Operations	Vol. 12 No. 3	230
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 3: Developing a Program of Quality Assurance and Continuous Quality Improvement	Vol. 12 No. 3	234
Litigating the Legality of Compounding: The Medical Center Pharmacy Case	Vol. 12 No. 3	238
Developing a Niche Marketing Strategy	Vol. 12 No. 3	242
Web 2.0 and Health 2.0: Are You In?	Vol. 12 No. 3	244
A Process Verification Model for Quality Assurance in a Compounding Pharmacy	Vol. 12 No. 3	247
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 7: Microbial Contamination Risk Levels, 12-Hour Use, and Immediate Use	Vol. 12 No. 3	252
Calculations	Vol. 12 No. 3	258
Standard Operating Procedure: Dealing with Patients Experiencing Pain: Presenting without a Prescription	Vol. 12 No. 3	259
African Scalp Lotion	Vol. 12 No. 3	260
Benzyl Benzoate Lotion	Vol. 12 No. 3	261
Calcium Gluconate 2.5% Topical Gel	Vol. 12 No. 3	262
Lubricating Gel	Vol. 12 No. 3	263
Meloxicam 0.3% Topical Gel	Vol. 12 No. 3	264
Miconazole Nitrate 2%, Deoxy-D-Glucose 0.2%, and Hydrocortisone 0.4% Lip Balm	Vol. 12 No. 3	265
Potassium Nitrate/Benzocaine/Tetracaine Dental Gel	Vol. 12 No. 3	266
Promethazine Hydrochloride 2.5-mg/mL Rectal Solution	Vol. 12 No. 3	267
Tolnaftate 1% Antifungal Microemulsion	Vol. 12 No. 3	268
Valsartan 4-mg/mL Oral Liquid	Vol. 12 No. 3	269
Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model	Vol. 12 No. 3	270
Chemical Stability of Naltrexone Hydrochloride Injection	Vol. 12 No. 3	274
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration	Vol. 12 No. 3	276
PostScription: A Contemporary Perspective on Compounding Education	Vol. 12 No. 3	279
PreScription: First Estriol, Then What?	Vol. 12 No. 4	284
Estriol: Women's Choice vs. A Manufacturer's Greed	Vol. 12 No. 4	286
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women	Vol. 12 No. 4	295
The Magic of Magnesium	Vol. 12 No. 4	306
Progesterone and Traumatic Brain Injury: A Review of Literature	Vol. 12 No. 4	310
Beyond-Use Dating, Labeling, Delivery, and Storage of Compounded and Repackaged Mediations in a Hospital or Institutional Setting	Vol. 12 No. 4	316
Microbial Air-Sampling Equipment, Part 2: Experiences of Compounding Pharmacists	Vol. 12 No. 4	321
Recommendations for Overcoming Barriers to Medication Therapy Management Implementation, Part 1: Review of Literature	Vol. 12 No. 4	329
Using Readily Available Technology to Start or Enhance Pharmacy-Based Immunization	Vol. 12 No. 4	334
Marketing for Your Community	Vol. 12 No. 4	338
Quality-Control Analytical Methods: Homogeneity of Dosing Forms	Vol. 12 No. 4	340
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating	Vol. 12 No. 4	344
Calculations	Vol. 12 No. 4	354
Chloroxylenol 1% and Chlorhexidine Diacetate 1% Topical Powder	Vol. 12 No. 4	355
Silicone Cream	Vol. 12 No. 4	356
Sodium Chloride 0.9% Ointment	Vol. 12 No. 4	357
Squalene 0.2% Cream	Vol. 12 No. 4	358
Sucralfate and Hyaluronic Acid Ointment	Vol. 12 No. 4	359
Tretinoin and (-)Alpha-Bisabolol Gel	Vol. 12 No. 4	360
Tretinoin and Dexpanthenol Gel	Vol. 12 No. 4	361
Ultrasonic Adhesive Gel	Vol. 12 No. 4	362
Vitamin A Suppository	Vol. 12 No. 4	363
Zirconium Oxide Lotion	Vol. 12 No. 4	364
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada	Vol. 12 No. 4	365
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration	Vol. 12 No. 4	368
Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms	Vol. 12 No. 4	372
PostScription: It Is Not Just What You Say…But How You Say It!	Vol. 12 No. 4	375
PreScription: Compounding Around the World	Vol. 12 No. 5	382
Canine Public Servants: Caring for Drug Detection Dogs	Vol. 12 No. 5	384
Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases	Vol. 12 No. 5	392
Veterinary Compounding for Myasthenia Gravis	Vol. 12 No. 5	398
Equine Anesthesia: Triple Drip	Vol. 12 No. 5	402
Publication Expansion of United States Pharmacopeial Convention's Veterinary Standards and Clinical Information	Vol. 12 No. 5	405
Golden Ticket to the United States Pharmacopeial Convention's Veterinary Internship	Vol. 12 No. 5	410
Medication Therapy Management Implementation, Part 2: Study Methodologies, Barriers, and Recommendations to Overcome Barriers	Vol. 12 No. 5	414
Insurance for the Compounding Pharmacy Business, Part 1: Who Is Covered?	Vol. 12 No. 5	420
Excipient Choices for Special Populations	Vol. 12 No. 5	426
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 4L Tips for "Last Minute" Preparations	Vol. 12 No. 5	432
Technology for the Patient-Centric Pharmacy	Vol. 12 No. 5	434
Marketing: Taking Your Show on the Road	Vol. 12 No. 5	438
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 9: Immediate-Use Compounded Sterile Preparations	Vol. 12 No. 5	440
Calculations	Vol. 12 No. 5	444
Aceclofenac 1.5% Gel-Cream	Vol. 12 No. 5	446
Acetaminophen 10-mg/mL Rectal Solution	Vol. 12 No. 5	447
Carnitine 400-mg/mL and Coenzyme Q10 10-mg/mL Solution	Vol. 12 No. 5	448
Dichlorobenzyl Alcohol Tooth Gel	Vol. 12 No. 5	449
Estradiol 0.1% Vaginal Solution	Vol. 12 No. 5	450
Flurandrenolide Topical Film	Vol. 12 No. 5	451
Ketoprofen 20% Topical Solution	Vol. 12 No. 5	452
Lidocaine Adhesive System Gel	Vol. 12 No. 5	453
Piroxicam 5% and Dexpanthenol 5% Gel	Vol. 12 No. 5	454
Propafenone 1.5-mg/mL Oral Liquid	Vol. 12 No. 5	455
Testing the Long-Term Stability of Vancomycin Ophthalmic Solution	Vol. 12 No. 5	456
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration	Vol. 12 No. 5	460
Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration	Vol. 12 No. 5	463
PostScription: The International Society of Pharmaceutical Compounding: A Discussion of Its Importance from the Perspective of ISPhC Leadership	Vol. 12 No. 5	467
Prescription: Is "Globalization" a Good Idea?	Vol. 12 No. 6	474
Arthritis Epidemiology Impacts Pharmacists	Vol. 12 No. 6	476
Compounding Challenges for Immunocompromised Patients	Vol. 12 No. 6	482
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism	Vol. 12 No. 6	488
Case Reports: Compounding to Relieve Arthritis Pain	Vol. 12 No. 6	498
Symbols: Historic and Current Uses	Vol. 12 No. 6	505
Medication Therapy Management Implementation, Part 3: Barriers and Recommendations to Overcome Barriers	Vol. 12 No. 6	508
Insurance for the Compounding Pharmacy Business, Part 2: What, When, and Where	Vol. 12 No. 6	514
Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations	Vol. 12 No. 6	524
Basics of Compounding: United States Pharmacopeia General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 10: First Revision: The Main Changes, Events, and Rationale	Vol. 12 No. 6	530
Branding: Give Your Small Business a Big Image	Vol. 12 No. 6	537
Calculations	Vol. 12 No. 6	539
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel	Vol. 12 No. 6	540
Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel	Vol. 12 No. 6	541
Glycerin, Sterile	Vol. 12 No. 6	542
Indomethacin 2% in Pluronic Lecithin Organogel	Vol. 12 No. 6	543
Ketorolac Tromethamine 2% Topical Gel	Vol. 12 No. 6	544
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules	Vol. 12 No. 6	545
Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream	Vol. 12 No. 6	546
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules	Vol. 12 No. 6	547
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules	Vol. 12 No. 6	548
Morphine Sulfate 20-mg and Prochlorperazine Maleate 10-mg Troches	Vol. 12 No. 6	549
Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties	Vol. 12 No. 6	550
Chemical Stability of Admixtures Containing Ziconotide 25 mcg/mL and Morphine Sulfate 10 mg/mL or 20 mg/mL During Simulated Intrathecal Administration	Vol. 12 No. 6	553
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System	Vol. 12 No. 6	558
PostScription: Supporting Compounding Around the World	Vol. 12 No. 6	565